Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project

Alzheimer's and Dementia

Volumn 13, Issue 2, 2017, Pages 186-195

  Ritchie, Karen ^a,b,j   Ropacki, Michael ^c   Albala, Bruce ^d   Harrison, John ^e,f   Kaye, Jeffrey ^g   Kramer, Joel ^h   Randolph, Christopher ⁱ   Ritchie, Craig W ^j  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c First Clinical Research   (United States)

^d EISAI INC   (United States)

^e METIS COGNITION LTD   (United Kingdom)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

Alzheimer's disease; Cognition; Neuropsychology; Preclinical

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; COGNITION; COHORT ANALYSIS; DISEASE COURSE; EPISODIC MEMORY; EXECUTIVE FUNCTION; FOLLOW UP; HIPPOCAMPUS; HUMAN; INCIDENCE; LONG TERM MEMORY; MILD COGNITIVE IMPAIRMENT; MOTOR PERFORMANCE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; OUTCOME ASSESSMENT; PAIRED ASSOCIATE LEARNING; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; SHORT SURVEY; SPATIAL MEMORY; SPATIAL ORIENTATION; VERBAL MEMORY; VERBAL MEMORY TEST; VISUAL ATTENTION; WORKING MEMORY; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; PRODROMAL SYMPTOM; PSYCHOLOGY;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION; HUMANS; NEUROPSYCHOLOGICAL TESTS; PRODROMAL SYMPTOMS;

EID: 85006295188     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.07.154     Document Type: Short Survey

References (45)

1. [1] Ritchie, K., Carrière, I., Ritchie, C.W., Berr, C., Artero, S., Ancelin, M.L., Can we design prevention programs to reduce dementia incidence ? A prospective study of modifiable risk factors. BMJ 341 (2010), 3885–3892.
2. [2] Barnes, D.E., Yaffe, K., The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10 (2011), 819–828.
3. [3] Reiman, E.M., Chen, K., Alexander, G.E., Caselli, R.J., Bandy, D., Osborne, D., et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101 (2004), 284–289.
4. [4] Scarmeas, N., Habeck, C.G., Stern, Y., Anderson, K.E., APOE genotype and cerebral blood flow in healthy young individuals. JAMA 290 (2003), 1581–1582.
5. [5] Alexopoulos, P., Richter-Schmidinger, T., Horn, M., Maus, S., Reichel, M., Sidiropoulos, C., et al. Hippocampal volume differences between healthy young Apolipoprotein E e2 and e4 carriers. J Alzheimers Dis 26 (2011), 207–210.
6. [6] Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., et al. Clinical and biomarker changes in Dominantly Inherited Alzheimer's Disease. N Engl J Med 367 (2012), 795–804.
7. [7] Ritchie, K., Ritchie, C.W., Yaffe, K., Skoog, I., Scarmeas, N., Is Alzheimer's disease really a disease of mid-life. Alzheimers Dement (N Y) 1 (2015), 122–130.
8. [8] Ritchie, C.W., Molinuevo, J.L., Truyen, L., Satlin, A., Van der Geyten, S., Lovestone, S., on behalf of the European Prevention of Alzheimer's Dementia (EPAD) Consortium. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry 3 (2016), 179–186.
9. [9] Jack, C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9 (2010), 119–128.
10. [10] Jack, C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: an up-dated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
11. [11] Ritchie, K., Carrière, I., Berr, C., Amieva, H., Dartigues, J.F., Ancelin, M.L., et al. The clinical picture of Alzheimer's disease in the decade before diagnosis: clinical and biomarker trajectories. J Clin Psychiatry 77 (2016), e305–e311.
12. [12] Ritchie, K., Kotzki, P.O., Touchon, J., Cristol, J.P., Characterisitics of Alzheimer's disease patients with and without ApoE e4 allele. Lancet 348 (1996), 960–961.
13. [13] Chen, K.H., Chuah, L.Y., Sim, S.K., Chee, M.W., Hippocampal region-specific contributions to memory performance in normal elderly. Brain Cogn 72 (2010), 400–407.
14. [14] Nestor, P.J., Fryer, T.D., Ikeda, M., Hodges, J.R., Retrospelnia cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease). Eur J Neurosci 18 (2003), 2663–2667.
15. [15] Rowe, C.C., Ng, S., Ackerman, U., Gong, S.J., Pike, K., Savage, G., Imaging beta amyloid burden in aging and dementia. Neurology 68 (2007), 1718–1725.
16. [16] Khan, U.A., Liu, L., Provenzano, F.A., Berman, D.E., Profaci, C.P., Sloan, R., et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci 17 (2014), 304–311.
17. [17] Moodley, K., Minati, L., Contarino, V., Prioni, S., Wood, R., Cooper, R., et al. Diagnostic differentiation of mild cognitive impairment due to Alzheimer's disease using a hippocampus-dependant test of spatial memory. Hippocampus 25 (2015), 939–951.
18. [18] Tu, S., Wong, S., Hodges, J.R., Irish, M., Piguet, O., Hornberger, M., Lost in spatial translation – A novel tool to objectively assess spatial disorientation in Alzheimer's disease and frontotemporal dementia. Cortex 67 (2015), 83–94.
19. [19] Jungwirth, S., Zehetmayer, S., Bauer, P., Weissgram, S., Tragl, K.H., Fischer, P., Prediction of Alzheimer dementia with short neuropsychological instruments. J Neural Transm (Vienna) 116 (2009), 1513–1521.
20. [20] Amieva, H., Jacqmin-Gadda, H., Orgogozo, J.M., Le Carret, N., Helmer, C., Letenneur, L., The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population based study. Brain 128 (2005), 1093–1101.
21. [21] Laukka, E.J., Macdonald, S.W., Fratiglioni, L., Bäckman, L., Preclinical cognitive trajectories differ for Alzheimer's disease and vascular dementia. J Int Neuropsychol Soc 18 (2012), 191–199.
22. [22] Rajan, K.B., Wilson, R.S., Weuve, J., Barnes, L.L., Evans, D.A., Cognitive impairment 18 years before clinical diagnosis of Alzheimer's disease dementia. Neurology 5 (2015), 1–8.
23. [23] Perrotin, A., Mormino, E.C., Madison, C.M., Hayenga, A.O., Jagust, W.J., Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol 69 (2012), 223–229.
24. [24] Song, Z., Insel, P.S., Buckley, S., Yohannes, S., Mezher, A., Simonson, A., Brain amyloid-beta burden is associated with disruption of intrinsic functional connectivity within the medial temporal lobe in cognitively normal elderly. J Neurosci 35 (2015), 3240–3247.
25. [25] Hedden, T., Oh, H., Younger, A.P., Patel, T.A., Meta-analysis of amyloid –cognition relations in cognitively normal adults. Neurology 80 (2013), 1341–1348.
26. [26] Bilgel, M., An, Y., Lang, A., Prince, J., Jedynak, B., Resnick, S.M., Trajectories of AD-related cognitive measures in a longitudinal sample. Alzheimers Dement 10 (2014), 735–742.
27. [27] Yotter, R.A., Doshi, J., Clark, V., Sojkova, J., Zhou, Y., Wong, D.F., et al. Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden. Neurobiol Aging 34 (2013), 2835–2842.
28. [28] Nutter-Upham, K.E., Saykin, A.J., Rabin, L.A., Roth, R., Wishart, H.A., Pare, N., et al. Verbal fluency performance in amnestic MCI and older adults with cognitive complaints. Arch Clin Neuropsychol 23 (2008), 229–241.
29. [29] Kennedy, K.M., Rodrigue, K.M., Devous, M.D., Hebrank, A.C., Bischof, G.N., Park, D.C., Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. Neuroimage 62 (2012), 1–8.
30. [30] Wilson, R.S., Leurgans, S.E., Boyle, P.A., Bennett, D.A., Cognitive Decline in Prodromal Alzheimer Disease and Mild Cognitive Impairment. Arch Neurol 68 (2011), 351–356.
31. [31] Duff, K., Foster, N.L., Dennett, K., Hammers, D.B., Zollinger, L.V., Christian, P.E., et al. Amyloid deposition and cognition in older adults: the effects of premorbid intellect. Arch Clin Neuropsychol 28 (2013), 665–671.
32. [32] Doraiswamy, P.M., Sperling, R.A., Coleman, R.E., Johnson, K.A., Reiman, E.M., Davis, M.D., et al. Amyloid-assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurology 79 (2012), 1636–1644.
33. [33] Kramer, J.H., Mungas, D., Possin, K.L., Rankin, K.P., Boxer, A.L., Rosen, H.J., et al. NIH EXAMINER: Conceptualization and Development of an Executive Function Battery. J Int Neuropsychol Soc 20 (2014), 11–19.
34. [34] Rentza, D.M., Amariglioa, R.E., Becker, J.A., Freya, M., Olsona, L.E., Frishea, K., et al. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia 49 (2011), 2776–2783.
35. [35] Grober, E., Sanders, A.E., Hall, C., Lipton, R.B., Free and cued selective reminding identifies very mild dementia in Primary Care. Alzheimer Dis Assoc Disord 24 (2010), 284–290.
36. [36] Amieva, H., Le Goff, M., Millet, X., Orgogozo, J.M., Peres, K., Barberger-Gateau, P., et al. Prodromal Alzheimer's Disease: Successive emergence of the clinical symptoms. Ann Neurol 64 (2008), 492–498.
37. [37] Grober, E., Hall, C.B., Lipton, R.B., Zonderman, A.B., Resnick, S.M., Kawas, C., Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 14 (2008), 266–278.
38. [38] Karantzoulis, S., Novitski, J., Gold, M., Randolph, C., The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in Detection and Characterization of Mild Cognitive Impairment due to Alzheimer's Disease. Arch Clin Neuropsychol 28 (2013), 837–844.
39. [39] England, H.B., Gillis, M.M., Hampstead, B.M., RBANS Memory indices are related to medial temporal lobe volumetrics in healthy older adults and those with mild cognitive impairment. Arch Clin Neuropsychol 29 (2014), 322–328.
40. [40] Hampstead, B.H., Stringer, A.Y., Stilla, R.F., Deshpande, G., Hu, X., Moore, A.B., et al. Activation and effective connectivity changes following explicit memory training for name-face pairs in patients with mild cognitive impairment: a pilot study. Neurorehabil Neural Repair 25 (2011), 210–222.
41. [41] Lim, Y.Y., Villemagne, V.L., Pietrzak, R.H., Ames, D., Ellis, K.A., Harrington, K., et al., for the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol Aging 36 (2015), 1239–1244.
42. [42] Ellis, K.A., Lima, Y.Y., Harrington, K., Ames, D., Bush, A.I., Darby, D., et al., and the AIBL Research Group. Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid-beta. J Alzheimers Dis 34 (2013), 861–871.
43. [43] Storandt, M., Mintun, M.A., Head, D., Morris, J.C., Cognitive decline and brain volume loss as signatures of cerebral amyloid peptide deposition identified with Pittsburgh Compound B. Arch Neurol 66 (2009), 1476–1481.
44. [44] Ritchie, K., de Roquefeuil, G., Ritchie, C.W., Besset, A., Poulain, V., Artero, S., et al. COGNITO: Computerized Assessment of Information Processing. J Psychol Psychother, 4, 2014, 136.
45. [45] Riley, K.P., Jicha, G.A., Davis, D., Abner, E.L., Cooper, G.E., Stilese, N., et al. Prediction of preclinical Alzheimer's Disease: longitudinal rates of change in cognition. J Alzheimers Dis 25 (2011), 707–717.